Supplementary Table 4 from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
收藏NIAID Data Ecosystem2026-05-25 收录
数据链接：
官方服务：
资源简介：
Supplementary Table 4. Tables with results of molecular analyses of Part C patients (PIK3CA and ESR1 mutation status in tissue and ctDNA, PTEN status in archival tissue)
创建时间：
2018-05-01
